Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2588-2595

  Leonetti, Carlo ^a   Biroccio, Annamaria ^a   Candiloro, Antonio ^a   Citro, Gennaro ^a   Fornari, Cristina ^a   Mottolese, Marcella ^a   Del Bufalo, Donatella ^a   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; HLA ANTIGEN; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENES, MYC; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032852873     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schuchter, L. M., Wohlganger, J., Fishman, E. K., MacDermott, M. L., and McGuire, W. P. Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma. J. Immunother., 12: 272-276, 1992.
2. Margolin, K. A., Doroshow, J. H., Akman, S. A., Leong, L. A., Morgan, R. J., Somlo, G., Rascko, J., Pereira, C., Yonemoto, L., and Ahn, C. Phase II trial of cisplatin and β-interferon in advanced malignant melanoma. J. Clin. Oncol., 10: 1574-1578, 1992.
3. Richards, J. M., Metha, N., Ramming, K., and Skosey, P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol., 10: 1338-1343, 1992.
4. Herlyn, M. Human melanoma: development and progression. Cancer Metastasis Rev., 9: 101-112, 1990.
5. Kerbel, R. S. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv. Cancer Res., 55: 87-132, 1990.
6. Clark, W. H. Tumour progression and the nature of cancer. Br. J. Cancer, 64: 631-644, 1991.
7. Ross, D. A., and Wilson, G. D. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br. J. Surg., 85: 46-51, 1998.
8. Grover, R., Ross, D. A., Richman, P. I., Robinson, B., and Wilson, G. D. c-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Eur. J. Surg. Oncol., 22: 342-346, 1996.
9. Lazaris, A. C., Theodoropoulos, G. E., Aroni, K., Saetta, A., and Davaris, P. S. Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch., 426: 461-467, 1995.
10. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ., 44: 41-47, 1993.
11. Dong, J., Naito, M., and Tsuruo, T. c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Oncogene, 15: 639-647, 1997.
12. Sklar, M. D., and Prochownik, E. V. Modulation of cisplatinum resistance in friend erythroleukemia cells by c-myc. Cancer Res., 51: 2118-2123, 1991.
13. Kinashi, Y., Akaboshi, M., Masunaga, S., Ono, K., and Watanabe, M. Resistance to 195mPt-radiolabeled cis-diaminedichloroplatinum (II) of shock cells transfected with various oncogenes. Radiat. Med., 16: 233-237, 1998.
14. Niimi, S., Nakagawa, K., Yokota, J., Tsunokawa, Y., Nishio, K., Terashima, Y., Shibuya, M., Terada, M., and Saijo, N. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer, 63: 237-241, 1991.
15. Leonetti, C., D'Agnano, I., Lozupone, F., Valentini, A., Geiser, T., Zon, G., Calabretta, B., Citro, G., and Zupi, G. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst., 88: 419-429, 1996.
16. Citro, G., D'Agnano, I., Leonetti, C., Perini, R., Bucci, B., Zon, G., Calabretta, B., and Zupi, G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res., 58: 283-289, 1998.
17. Steel, G. G. Growth Kinetics of Tumours. Oxford, United Kingdom: Clarendon Press, 1977.
18. Curt, G. A., Clendennin, N. J., and Chabner, B. A. Drug resistance in cancer. Cancer Treat. Rep., 68: 89-99, 1984.
19. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cis-platin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
20. Schlagbauer-Wadl, H., Griffioen, M., Van Elsas, A., Schrier, P. I., Pustelnik, T., Eichler, H. G., Wolff, K., Pehamberger, H., and Jansen, B. Influence of increased c-myc expression on the growth characteristics of human melanoma. J. Invest. Dermatol., 112: 332-336, 1999.
21. Versteeg, R., Noordermeer, I. A., Krüse-Wolters, M., Ruiter, D. J., and Schrier, P. I. c-myc down-regulates class I HLA expression in human melanomas. EMBO J., 7: 1023-1029, 1988.
22. Blom, D. J., Mooy, C. M., Luyten, G. P., Kerkvliet, S., Ouwerkerk, I., Zwinderrnan, A. H., Schrier, P. I., and Jager, M. J. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. J. Pathol., 181: 75-79, 1997.
23. Van Waardenburg, R. C. A. M., Meuer, C., Burger, H., Nooter, K., De Vries, E. G. E., Mulder, N. H, and De Jong, S. Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line. Int. J. Cancer, 73: 544-550, 1997.
24. Walker, T. L., White, J. D., Esdale, W. J., Burton, M. A., and DeCruz, E. E. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br. J. Cancer, 73: 610-614, 1996.
25. Eliopoulos, A., Kerr, D. J., and Spandidos, D. A. The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cells. Anticancer Drugs, 2: 597-601, 1991.
26. Eliopoulos, A. G., Kerr, D. J., Maurer, H. R., Hilgard, P., and Spandidos, D. A. Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem. Pharmacol., 50: 33-38, 1995.